Considering that neither Nrf2 nor NQO1 alone is predictive of NSCLC outcomes and their linkage in the context of oxidative stress and tumor progression, we combined Nrf2 and NQO1 as a co-factor in this study and investigated the possibility of their usefulness as prognostic biomarkers in NSCLC patients. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.